Intravenous Ferric Carboxymaltose Compared to Oral Iron in the Treatment of Iron Deficiency Anaemia in Pregnancy

Background Iron deficiency Anaemia (IDA) in pregnancy is a global phenomenon and causes significant maternal morbidity and mortality worldwide. Effective management of IDA in pregnancy is currently lacking. Ferric Carboxymaltose (FCM) is a newer treatment option which is both effective and well tolerated. Objectives To compare the efficacy and tolerance of FCM with oral iron in the treatment of IDA in pregnancy. Materials and Methods This is a prospective study carried out over a period of 12 months in the department of Obstetrics and Gynaecology, Gauhati Medical College and Hospital, Guwahati, India. Pregnant women (n=100), between 12-36 weeks with IDA were randomised 11 to FCM (500 mg iv in 250 ml NS) or oral iron (200 mg elemental iron per day orally) for 6 weeks. Results and observations Rise in mean Hb and mean serum ferritin levels after 3 weeks and 6 weeks was more in FCM Group than Oral Group. The difference was statistically significant. Also, treatment with FCM led to fewer gastrointestinal adverse events. Conclusion During the second and third trimesters, FCM has improved efficacy than first line oral iron treatment and is well tolerated in pregnant women.